Keytruda

(Image: Getty/Monsitj)

Sales of Keytruda leads Merck to strong Q2

By Ben Hargreaves

Sales of immunotherapy treatment, Keytruda, were up by 58% year-on-year, which led Merck to a sales increase of 12% overall compared to 2018.